Search Results - "Sana, Sherjeel"

Phase I trial of intravesical Bacillus Calmette–Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette–Guérin treatment by Alanee, Shaheen, Sana, Sherjeel, El-Zawahry, Ahmed, Peabody, James, Pearce, Tiffany, Adams, Nicole, Deebajah, Mustafa, Crabtree, Jane, Delfino, Kristin, McVary, Kevin, Robinson, Kathy, Rao, Krishna

“…Objectives We conducted the first phase I dose-escalation trial (NCT02324582) of intravesical Bacillus Calmette–Guérin (BCG) in combination with systemic…”
Get full text

Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with high-risk non-muscle invasive bladder cancer by Jamil, Marcus L, Deebajah, Mustafa, Sood, Akshay, Robinson, Kathy, Rao, Krishna, Sana, Sherjeel, Alanee, Shaheen

“…IntroductionThe initial treatment for high-risk non-muscle invasive bladder cancer (NMIBC) is endoscopic resection of the tumour followed by BCG therapy. In…”
Get full text

Central Nervous System Prophylaxis Utilization in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Within a Large Community Health System by Williams, Michael J, Atienza, Sol D, Aranda, Renee H, Flint, Kayleigh B, Sana, Sherjeel, Medlin, Stephen C, Gul, Zartash, Sanchez, Federico A, Thompson, Michael A

“…The impact of central nervous system (CNS) prophylaxis in diffuse large B-cell lymphoma (DLBCL) is contentious. The CNS International Prognostic Index (IPI)…”
Get full text

Phase I trial of safety of combining BCG with pembrolizumab in patients with high grade superficial bladder cancer unresponsive to previous intravesical therapy by Alanee, Shaheen Riadh, Robinson, Kathy, Sana, Sherjeel

“…Abstract only TPS111 Background: Bacille Calmette-Guerin (BCG) is the most effective agent in the treatment of high grade superficial bladder cancer (HGSBC);…”
Get full text

Incidence of cardiac events in patients with MDS or AML receiving azacitidine or decitabine within a large community health system by Naffakh, Noor, Williams, Michael, Patel, Priyam, Pedersen, Rachel, Peterson, Michael, DeFranco, Anthony, Medlin, Stephen, Sana, Sherjeel, Gul, Zartash

“…e19074 Background: Hypomethylating agents (HMA) such as decitabine and azacitidine are frontline therapies for myelodysplastic syndrome (MDS) and acute myeloid…”
Get full text

Reduced blood product utilization via implementation of an anemia clinic and consult service in a large health system hospital by Bowers, Reid Christian, Korman, Sandra Tomany, Thompson, Michael A., Sana, Sherjeel, Pant, Manish Krishna, Sanchez, Federico Augusto

“…e18716 Background: An Anemia Clinic program was started Sept. 2016 as part of system wide implementation of Patient Blood Management (PBM) initiated in 2015…”
Get full text

Reduced blood product utilization via implementation of an anemia clinic and consult service in a large health system hospital by Bowers, Reid Christian, Korman, Sandra Tomany, Thompson, Michael A., Sana, Sherjeel, Pant, Manish Krishna, Sanchez, Federico Augusto

“…e18799 Background: An Anemia Clinic program was started Sept. 2016 as part of system wide implementation of Patient Blood Management (PBM) initiated in 2015…”
Get full text

Reduced blood product utilization via implementation of an anemia clinic and consult service in a large health system hospital by Bowers, Reid Christian, Korman, Sandra Tomany, Thompson, Michael A., Sana, Sherjeel, Pant, Manish Krishna, Sanchez, Federico Augusto

“…Abstract only e18654 Background: An Anemia Clinic program was started Sept. 2016 as part of system wide implementation of Patient Blood Management (PBM)…”
Get full text

Comparison of intermittent intravenous tacrolimus to continuous tacrolimus in adult allogeneic stem cell transplant recipients by Williams, Michael, Gul, Zartash, Graff, Justin, Mejaki, Brittany, Sana, Sherjeel, Medlin, Stephen

“…Initial continuous intravenous (CIV) tacrolimus (0.03 mg/kg/day based on ideal body weight [IBW]) has been favored for graft versus host disease (GVHD)…”
Get full text

Abstract CT047: Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous Pembrolizumab in high grade nonmuscle invasive bladder cancer by Alanee, Shaheen, Zawahry, Ahmed El, Sana, Sherjeel, McVary, Kevin, Robinson, Kathy, Rao, Krishna A.

“…Abstract PURPOSE: A phase I trial of intravesical bacillus Calmette-Guérin (BCG) in combination with systemic pembrolizumab was conducted in patients with high…”
Get full text

MP43-09 PHASE I TRIAL OF INTRAVESICAL BACILLUS CALMETTE-GUéRIN COMBINED WITH INTRAVENOUS PEMBROLIZUMAB IN HIGH GRADE NONMUSCLE INVASIVE BLADDER CANCER by Alanee, Shaheen, El-Zawahry, Ahmed, McVary, kevin, Deebajah, Mustafa, Sana, Sherjeel, Robinson, Kathy, Rao, Krishna

Get full text

Reduced blood product utilization via implementation of an anemia clinic and consult service in a large health system hospital by Bowers, Reid Christian, Thompson, Michael A., Korman, Sandra Tomany, Sana, Sherjeel, Pant, Manish Krishna, Sanchez, Federico Augusto

“…Abstract only e14142 Background: An Anemia Clinic program was started Sept. 2016 as part of system wide implementation of Patient Blood Management (PBM)…”
Get full text

Assessment of changes in the international prostate symptom score for patients enrolled in a phase I trial of intravesical bacillus Calmette-Guérin combined with intravenous pembrolizumab for recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous bacillus Calmette-Guérin treatment by Montgomery, Jazzmyne T., Sana, Sherjeel, El-Zawahry, Ahmed, Peabody, James O., Pearce, Tiffany, Adams, Nicole, Deebajah, Mustafa, Dynda, Danuta, Babaian, Kara N., Crabtree, Jane, Delfino, Kristin, McVary, Kevin, Robinson, Kathy, Rao, Krishna A., Alanee, Shaheen Riadh

“…e16553 Background: We conducted the first phase I dose-escalation trial (NCT02324582) of intravesical Bacillus Calmette-Guérin (BCG) in combination with…”
Get full text

Cancer treatment in Pakistan: challenges & obstacles by Aziz, Zeba, Sana, Sherjeel

“…There is no population based tumor registry in Pakistan except for Karachi. A Department based tumor registry was established to determine the patterns of…”
Get more information

MP54-02 TWO-YEAR EFFICACY FOLLOW-UP OF A PHASE I TRIAL OF INTRAVESICAL BACILLUS CALMETTE-GUÉRIN COMBINED WITH INTRAVENOUS PEMBROLIZUMAB IN RECURRENT OR PERSISTENT HIGH-GRADE NON-MUSCLE-INVASIVE BLADDER CANCER AFTER PREVIOUS BACILLUS CALMETTE-GUÉRIN TREATMENT by Alanee, Shaheen, Montgomery, Jazzmyne, Sana, Sherjeel, El-Zawahry, Ahmed, Peabody, James, Pearce, Tiffany, Adams, Nicole, Deebajah, Mustafa, Dynda, Danuta, Babaian, Kara, Crabtree, Jane, Delfino, Kristin, McVary, Kevin, Robinson, Kathy, Rao, Krishna

Get full text

Reduced blood product utilization via implementation of an anemia clinic and consult service in a large health system hospital: Focus on cardiovascular patients by Bowers, Reid Christian, Korman, Sandra Tomany, Thompson, Michael A., Pant, Manish Krishna, Sana, Sherjeel, Sanchez, Federico Augusto

“…Abstract only e18014 Background: As part of a system wide implementation of Patient Blood Management (PBM), an Anemia Clinic program was implemented at St…”
Get full text

Use of Type 1 Interferon-Alpha 2a for Relapse Prevention in Allogeneic Stem Cell Transplant by Williams, Michael, Mejaki, Brittany, Graff, Justin, Sana, Sherjeel, Medlin, Stephen, Gul, Zartash

“…Peginterferon-alpha (pegIFNα), a type 1 IFN that may enhance graft versus leukemia (GVL) effect, has limited evidence to support its use for relapse prevention…”
Get full text

Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin Treatment by Montgomery, Jazzmyne, Lybbert, Daniel, Sana, Sherjeel, El-Zawahry, Ahmed, Peabody, James, Pearce, Tiffany, Adams, Nicole, Deebajah, Mustafa, Dynda, Danuta, Babaian, Kara, Crabtree, Jane, Delfino, Kristin, McVary, Kevin, Robinson, Kathy, Rao, Krishna, Alanee, Shaheen

“…To report urinary bother, urinalysis changes, disease-free survival (DFS), and overall survival (OS) over 2 years for subjects enrolled in a phase I…”
Get full text

358 - Comparison of Intermittent Intravenous Tacrolimus to Continuous Tacrolimus in Allogeneic Stem Cell Transplant Recipients by Williams, Michael, Mejaki, Brittany, Graff, Justin, Gul, Zartash, Sana, Sherjeel, Medlin, Stephen

Get full text

Comparison of Intermittent Intravenous Tacrolimus to Continuous Tacrolimus in Allogeneic Stem Cell Transplant Recipients by Williams, Michael, Mejaki, Brittany, Graff, Justin, Gul, Zartash, Sana, Sherjeel, Medlin, Stephen

Get full text